Tribendimidine in the treatment of liver fluke infection in China

ISRCTN ISRCTN80829842
DOI https://doi.org/10.1186/ISRCTN80829842
Secondary identifying numbers N/A
Submission date
07/03/2012
Registration date
20/03/2012
Last edited
27/08/2013
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Clonorchiasis, a disease caused by the oriental liver fluke Clonorchis sinensis, is of considerable public health importance. The disease is constantly present in the People’s Republic of China, Taiwan, Vietnam, and the Republic of Korea, where an estimated 601 million people are at risk and more than 35 million people are infected. There is currently no vaccine available for prevention of clonorchiasis and chemotherapy is the main treatment. However, chemotherapy of clonorchiasis relies on a single drug called praziquantel. Efforts are underway to administer praziquantel more widely, in preventive chemotherapy campaigns. There is some concern that this strategy might result in the development and spread of drug-resistant parasites. There is a need for discovery and development of new drugs. The aim of this study is to assess how well oral tribendimidine works in patients infected with C. sinensis.

Who can participate?
75 individuals with a parasitological-confirmed infection with C. sinensis

What does the study involve?
Patients will be randomly allocated to one of three groups:
- single oral dose of 400 mg tribendimidine
- oral doses of 400 mg tribendimidine daily for 3 days
- praziquantel (25 mg/kg 3 times a day) for 2 consecutive days

What are the possible benefits and risks of participating?
The two drugs which are compared are well known, widely used and have little adverse events. All children enrolled in the study will benefit from a treatment against liver fluke infection and soil transmitted helminths. All diagnosed parasitic infections will be treated according to national guidelines.

Where is the study run from?
Guangdong province, China.

When is study starting and how long is it expected to run for?
The study will last for 5-6 weeks and will take place in March/April 2012.

Who is funding the study?
The study will be funded by DFID/Wellcome Trust/MRC.

Who is the main contact?
Professor Jennifer Keiser

Contact information

Prof Jennifer Keiser
Scientific

Socinstr. 57
Basel
4051
Switzerland

Study information

Study designRandomized exploratory open-label phase II trial with three treatment arms
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleTribendimidine in the treatment of Clonorchis sinensis infection in the People’s Republic of China
Study objectivesTribendimidine achieves a higher efficacy than praziquantel in the treatment of Clonorchis infections

Follow up to http://www.controlled-trials.com/ISRCTN23425032
Ethics approval(s)Ethikkomission Beider, Basel, 09 February 2012 ref: 375/11
Health condition(s) or problem(s) studiedLiver fluke infections (Clonorchis sinesis)
InterventionGroup 1: single oral dose of 400 mg tribendimidine
Group 2: oral doses of 400 mg tribendimidine daily for 3 days
Group 3: praziquantel (25 mg/kg 3 times a day) for 2 consecutive days

Follow up is 21 days after treatment. Praziquantel brand names are Biltricide® and Cesol®.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase II
Drug / device / biological / vaccine name(s)Praziquantel, tribendimidine
Primary outcome measureCure rates and egg reduction rates three weeks after treatment:
For diagnosis three stool samples will be collected before and after treatment. From each stool sample three Kato-Katz thick smears will be examined. Additionally 1g of stool will be preserved for later diagnosis with the ether concentration method.
Secondary outcome measuresAdverse events due to specific treatment:
Participants will be monitored 3 hours after treatment. 24 hours after each day of treatment they will be asked with a standard questionnaire for adverse events.
Overall study start date10/03/2012
Completion date10/05/2012

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants75
Key inclusion criteria1. Patients (adults aged ≥18 years) infected with C. sinensis, as assessed by the presence of eggs in the stool
2. Signed written informed consent
3. Able and willing to be examined by a study physician at the beginning of the study and at the end-of study follow-up survey (3 - 4 weeks post-treatment)
4. Able and willing to provide multiple stool samples at the beginning and end of study
5. Absence of major systemic illnesses, psychiatric and neurological disorders as assessed by the medical doctor, upon initial clinical assessment
6. No known or reported hypersensitivity to tribendimidine or praziquantel
7. No known or reported history of chronical illness as cancer, diabetes, chronic heart, liver or renal disease
8. For females, not pregnant in the first trimester, as assessed by a female nurse (interview and pregnancy test if need be), upon initial clinical assessment
Key exclusion criteria1. For females, pregnancy in first trimester
2. Presence of any abnormal medical condition, judged by the study physician
3. History of acute or severe chronic disease
4. Known or reported hypersensitivity to tribendimidine or praziquantel
5. Known or reported psychiatric or neurological disorders
6. Use of any anthelmintic within the past month
7. Attending other clinical trials during the study
8. Absence of signed written informed consent sheet
Date of first enrolment10/03/2012
Date of final enrolment10/05/2012

Locations

Countries of recruitment

  • China
  • Switzerland

Study participating centre

Socinstr. 57
Basel
4051
Switzerland

Sponsor information

Medical Research Council (UK)
Research council

One Kemble Street
London
WC2B 4AN
United Kingdom

ROR logo "ROR" https://ror.org/03x94j517

Funders

Funder type

Government

Department For International Development [DFID] (UK)

No information available

Medical Research Council (MRC) (UK)
Government organisation / National government
Alternative name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC
Location
United Kingdom
Wellcome Trust (UK) ref: G1100699
Private sector organisation / International organizations
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/04/2013 Yes No